PeptideDeepDiveSemax & Selank: Evidence, Legal Status & How They Compare
Two Russian-origin peptides with a genuine clinical history, studied for cognition and anxiety rather than tissue repair — and a regulatory picture that looks nothing like BPC-157’s in the UK and EU.
The Short Answer
Semax and Selank are synthetic peptides developed in Russia, structurally derived from fragments of ACTH (Semax) and tuftsin (Selank). Both target the central nervous system rather than soft tissue — Semax is studied for cognitive and neuroprotective effects, Selank for anxiolytic and immune-modulating effects. This puts them in a different category from the tissue-repair peptides covered elsewhere on this site, like BPC-157 and TB-500.
Both hold formal pharmaceutical registration in Russia, where they’ve been used clinically for decades. Neither has FDA, MHRA, or EMA approval, and neither is authorised for medical use in the UK, Ireland, Germany, or elsewhere in the EU.
How They’re Thought to Work
Semax is studied for effects on brain-derived neurotrophic factor (BDNF) expression and neuroprotective signalling, with proposed applications in cognitive support and stroke recovery contexts within Russian clinical practice. Selank is studied for modulation of GABA and monoamine pathways linked to anxiety, alongside reported immunomodulatory effects. Both are administered intranasally in their Russian clinical formulations.
Evidence: Russian Registration vs. Western Clinical Trials
This is the key nuance with Semax and Selank compared to most other peptides discussed on this site: they have a genuine, decades-long clinical history — but almost entirely within the Russian pharmaceutical and research system, under different regulatory standards than FDA/EMA-style randomised controlled trials. Western-standard, peer-reviewed controlled trials remain limited, and the existing Russian-language literature has not been independently replicated to the extent Western regulators typically require for approval.
No FDA, MHRA, or EMA-validated human dosing exists for either compound, and long-term safety data outside the Russian clinical context is limited. This article does not provide dosing guidance.
Are Semax & Selank Legal in the UK, Ireland, Germany & the EU?
Neither compound is approved as a medicine in any of these jurisdictions, regardless of their Russian registration status. None of the below is legal advice.
Neither Semax nor Selank has UK marketing authorisation or is a licensed medicine under the Human Medicines Regulations 2012. Neither is a controlled drug, but neither can legally be sold or supplied with medicinal claims — both are marketed as research chemicals.
Not authorised as medicines by the HPRA and not scheduled as controlled substances — the same unregulated “research use only” category found across the EU.
No marketing authorisation under the Arzneimittelgesetz. Their Russian pharmaceutical registration carries no legal weight for sale or use in Germany.
Not authorised by the Dutch medicines evaluation board; sold under the same “research chemical” framing used across the EU.
Under EU medicines law (Directive 2001/83/EC), a product marketed with a medicinal claim requires an EU marketing authorisation — something neither compound holds, irrespective of their status elsewhere.
Semax & Selank vs. BPC-157 & TB-500
| Peptide | Target system | Evidence base | Regulatory footing |
|---|---|---|---|
| Semax / Selank | Central nervous system (cognition / anxiety) | Decades of Russian clinical use; limited Western trials | Registered in Russia; no FDA/MHRA/EMA approval |
| BPC-157 | Tendon, ligament, muscle & gut repair | Essentially none (1 small uncontrolled study) | No approval anywhere; FDA compounding review pending |
| TB-500 | Soft-tissue repair | Limited clinical-context data | No approval anywhere; FDA compounding review pending |
See the full recovery peptides comparison for GHK-Cu, KPV, MOTS-c and GLP-1 medicines too.
Semax and Selank’s Russian pharmaceutical registration is a genuinely different evidence situation than BPC-157’s — but a foreign registration is not the same as UK, Irish, German, or EU authorisation. Both remain unapproved, unregulated research chemicals everywhere covered in this guide.
Frequently Asked Questions
Are Semax and Selank legal in the UK?
Neither has UK marketing authorisation or is a licensed medicine, though neither is a controlled drug. Both are sold as research chemicals.
What are Semax and Selank studied for?
Semax for cognitive and neuroprotective effects; Selank for anxiolytic and immunomodulatory effects. Both target the central nervous system.
Are Semax and Selank approved medicines anywhere?
Both hold pharmaceutical registration in Russia. Neither has FDA, MHRA, or EMA approval, and neither is authorised in the UK, Ireland, Germany, or elsewhere in the EU.
How is Semax different from BPC-157?
Semax targets the central nervous system with a long Russian clinical history and formal drug registration; BPC-157 targets tissue repair and has no pharmaceutical approval anywhere.
References
- Russian Federation pharmaceutical registry entries for Semax and Selank (Russian Ministry of Health).
- UK Human Medicines Regulations 2012; MHRA guidance on unlicensed medicines.
- Health Products Regulatory Authority (HPRA), Ireland — authorised medicines and controlled substances listings.
- Arzneimittelgesetz (AMG), Germany — provisions on marketing authorisation of medicinal products.
- Directive 2001/83/EC on the Community code relating to medicinal products for human use.